Treace Medical Concepts, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Treace Medical Concepts, Inc. (TMCI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$49.53 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-02-27
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$4.41M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$12.13M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$17.23M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$9.04M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$49.53M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$42.81M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$20.75M.
- Treace Medical Concepts, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$4.31M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$49.53M 10-K · filed 2024-02-27 | |||
| 2022-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$16.55M derived: sum of 2 quarters · filed 2024-02-27 | -$33.78M derived: sum of 3 quarters · filed 2024-02-27 | -$42.81M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$12.13M 10-Q · filed 2022-11-09 | -$29.37M derived: sum of 2 quarters · filed 2022-11-09 | -$38.40M 10-Q · filed 2022-11-09 | -$45.02M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$17.23M 10-Q · filed 2022-08-10 | -$26.27M 10-Q · filed 2022-08-10 | -$32.89M derived: sum of 3 quarters · filed 2024-02-27 | -$39.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$9.04M 10-Q · filed 2022-05-06 | -$15.65M derived: sum of 2 quarters · filed 2024-02-27 | -$22.07M derived: sum of 3 quarters · filed 2024-02-27 | -$27.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$6.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$13.04M derived: sum of 2 quarters · filed 2024-02-27 | -$18.16M derived: sum of 3 quarters · filed 2024-02-27 | -$20.75M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$6.42M 10-Q · filed 2022-11-09 | -$11.54M derived: sum of 2 quarters · filed 2022-11-09 | -$14.13M 10-Q · filed 2022-11-09 | -$11.72M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | -$5.12M 10-Q · filed 2022-08-10 | -$7.71M 10-Q · filed 2022-08-10 | -$5.31M derived: sum of 3 quarters · filed 2023-03-08 | -$8.12M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | -$2.59M 10-Q · filed 2022-05-06 | -$184.00K derived: sum of 2 quarters · filed 2023-03-08 | -$3.00M derived: sum of 3 quarters · filed 2023-03-08 | -$5.13M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$410.00K derived: sum of 2 quarters · filed 2023-03-08 | -$2.54M derived: sum of 3 quarters · filed 2023-03-08 | -$4.31M 10-K · filed 2023-03-08 |
| 2020-09-30 | -$2.82M 10-Q · filed 2021-11-04 | -$4.95M derived: sum of 2 quarters · filed 2021-11-04 | -$6.71M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$2.13M 10-Q · filed 2021-08-05 | -$3.90M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$1.76M 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | -$4.91M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |